Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06532357 · ClinicalTrials.gov registry record
A Study to Learn About the Benefit of Rimegepant Versus Triptans in Migraine Buddy App Users.
A clinical trial, sponsored by Pfizer.
- Completed
- Registry status
- 1,536
- Enrollment target
NCT06532357: Completed study, sponsored by Pfizer.
NCT06532357 is a clinical trial that has completed, run by Pfizer. The registered enrollment target is 1,536 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06532357 has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 1,536 participants
- Enrollment target
Study Summary
The purpose of this study is to collect information of the US users from the Migraine Buddy app between 20 October 2023 and 20 May 2024. Patients who used Nurtec and/or triptans as an acute treatment for migraine, with or without a background of preventive treatment (anti-CGRP, Botox or oral migraine preventive medications) and completed a survey were eligible for this study. Acute treatment is a short-term treatment. The aim of this retrospective analysis was to learn about the user´s satisfaction with Nurtec or the triptan. The level of satisfaction with Nurtec will be compared to the level of satisfaction with triptans. The benefit of this study is the real-life setting of the information collected. This means that the users were using the Migraine Buddy app for tracking their migraines in real life.
Primary Outcome
Participants responded about satisfaction with treatment for pain intensity using following responses: extremely satisfied, satisfied, slightly satisfied, neither satisfied nor dissatisfied, slightly dissatisfied, dissatisfied, extremely dissatisfied. Based on participants responses, the respondents were grouped into those who were satisfied (reported extremely satisfied/ satisfied/ slightly satisfied), neutral (reported neither satisfied nor dissatisfied) or dissatisfied (reported slightly diss
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,536 participants |
| Start Date | 2024-06-09 |
| Est. Completion | 2024-06-10 |
What the finished NCT06532357 record still lists
NCT06532357 is an observational study that tracks outcomes without assigning an intervention. Its 1,536 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT06532357 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06532357 about?
NCT06532357 is a clinical study titled "A Study to Learn About the Benefit of Rimegepant Versus Triptans in Migraine Buddy App Users.". The purpose of this study is to collect information of the US users from the Migraine Buddy app between 20 October 2023 and 20 May 2024. Patients who used Nurtec and/or triptans as an acute treatment for migraine, with or without a background of preventive treatment (anti-CGRP, Botox or oral migrain...
What is the current status of trial NCT06532357?
This trial is currently completed. The enrollment target is 1,536 participants. The study started on 2024-06-09. Estimated completion is 2024-06-10.
Who is sponsoring clinical trial NCT06532357?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06842875 · 1,536 participants · NA
Rhode Island - Statewide Postpartum Hypertension Remote Surveillance
- NCT03435796 · 1,541 participants · Phase 2
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
- NCT06393374 · 1,530 participants · Phase 3
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- NCT07114510 · 1,530 participants · NA
Optimal Ventilation for Cardiac Arrest
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI